GlycoNex

GlycoNex, Inc. was established in 2001 as the first biotechnology company in Taiwan to combine "cancer-related glycan antigens" with "human monoclonal antibodies" for development. Since its founding, GlycoNex has consistently focused on innovative antibody drug development, concentrating on three major areas: Antibody-Drug Conjugates (ADCs), Pro-antibodies, and biosimilars, gradually building an internationally competitive R&D and manufacturing platform. The company is also simultaneously expanding its CDMO services, having established a 200L antibody production line compliant with GMP standards, with the capability to provide manufacturing for Phase I clinical trial drugs.